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Background: Attention-deficit/hyperactivity disorder (ADHD) is a common condition that often 
results in child and family functional impairments. Although there are evidence-based treatment 
modalities available, implementation of and persistence with treatment plans vary with patients. 
Family preferences also vary and may contribute to variability in treatment utilization.
Objective: The objective of this study is to describe the evidence-based treatments available 
for ADHD, identify patterns of use for each modality, and examine patient and parent treatment 
preferences.
Method: Literature review.
Results: Treatment options differ on benefits and risks/costs. Therefore, treatment decisions are 
preference sensitive and depend on how an informed patient/parent values the tradeoffs between 
options. Literature on patient and parent ADHD treatment preferences is based on quantitative 
research assessing the construct of treatment acceptability and qualitative and quantitative 
research that assesses preferences from a broader perspective. After a child is diagnosed with 
ADHD, a variety of factors influence the initial selection of treatment modalities that are utilized. 
Initial parent and child preferences are shaped by their beliefs about the nature of the child’s 
problems and by information (and misinformation) received from a variety of sources, including 
social networks, the media, and health care providers. Subsequently, preferences become further 
informed by personal experience with various treatment modalities. Over time, treatment plans 
are revisited and revised as families work with their health care team to establish a treatment 
plan that helps their child achieve goals while minimizing harms and costs.
Conclusions: Studies have not been able to determine the extent to which utilization rates are 
consistent with the underlying distribution of informed patient/parent treatment preferences. 
There are challenges to ensure that patient/parent preferences are consistently well informed, 
elicited, and discussed in the treatment planning process. Interventions are needed to promote 
such interactions.
Keywords: attention-deficit/hyperactivity disorder, ADHD, adherence, preferences, physician–
patient/parent communication, collaborative/shared decision making
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral condition 
that often results in academic, social, and family functional impairments. ADHD is 
prevalent, as 8.7% of children aged 8–15 years in the US meet diagnostic criteria 
for ADHD.1 Fortunately, there are evidence-based treatment modalities available. 
However, implementation of and persistence with treatment plans vary with patients. 
Family preferences contribute to variability in treatment implementation and adherence 
to treatment. Further, familial preferences appear to vary across treatment modalities. Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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The purpose of this review is to describe the evidence-based 
treatments available for ADHD, identify patterns of use for 
each modality, and examine patient and parent treatment 
preferences. This synthesis of information will hopefully 
inform future research in order to better understand the 
relationship between preferences and treatment utilization 
as well as interventions to improve treatment planning for 
children with ADHD.
Study identification
Studies included in this review were found in the MedLine and 
PsychInfo databases by crossing the terms “attention   deficit 
hyperactivity disorder”, “attention deficit disorder”, and 
“ADHD” with key terms, including “preferences”, “adher-
ence”, “treatment”, “management”, “guideline”, “  primary 
care”, and “communication”. Among included articles, 
a secondary review of cited references was performed.
Evidence-based ADHD treatment options
The Multimodal Treatment Study of Children with ADHD 
(MTA)2 provides evidence to support the use of 1) psycho-
social treatments alone, 2) medication alone, or 3) combined 
treatment (eg, both psychosocial and medication treatments). 
In this review we describe each treatment   modality; provide 
an estimate for the likelihood of benefit; identify possible 
shortcomings, including possible harms, costs, and barriers 
to implementation; and provide estimates for the use of and 
persistence with each modality. We limit our discussion to 
treatment modalities employed in the MTA study because 
these are the only modalities endorsed in prominent ADHD 
treatment guidelines.3,4 Although additional treatment 
modalities are increasingly being used5–7 and tested,8 none 
is endorsed in the current treatment guidelines.3,4
Psychosocial treatments
Psychosocial approaches to treatment can cover a range of 
specific interventions, but most of the existing evidence-based 
interventions support two primary components: direct 
contingency management and clinical behavior therapy. Direct 
contingency management focuses on direct control of conse-
quences for target behavior. Clinical behavior therapy involves 
teaching parents and/or teachers to implement strategies for 
managing ADHD in everyday settings. The MTA study 
included both components of psychosocial intervention as part 
of its psychosocial treatment strategy. Families participated 
in parent training groups, a school-based intervention, and 
a summer treatment program.2 The parent training groups 
involved 27 group (six families/group) and eight individual 
sessions. Training focused on teaching parents strategies 
(eg, giving effective commands, setting gradual goals, and 
using reward systems) to encourage desired behaviors and 
eliminate problem behaviors. The school-based intervention 
involved teachers learning classroom behavior management 
strategies during 10–16 training sessions and paraprofessional 
aides working one on one with children for half the school 
day for up to 60 days to improve classroom behaviors. 
A teacher-completed daily report card was used to communi-
cate child performance to parents, who reinforced behavior 
with home-based rewards. Finally, children attended a summer 
treatment program 9 h a day, 5 days/week, for 8 weeks. 
  Summer treatment program psychosocial   interventions were 
group based and delivered in recreational and classroom 
settings to improve social skills and classroom behaviors.
At the end of the 14-month MTA study, 34% of children 
who received these intensive psychosocial treatments (with-
out any medication) improved to the point of ADHD symptom 
remission (ie, they were no more inattentive, hyperactive, or 
impulsive than the average child their age without ADHD).9 
No child or parent in the MTA study reported harm from 
the psychosocial interventions.   However, there are potential 
shortcomings from these   treatments.   Obviously, parents 
and children need to invest time and effort into developing 
new skills for these approaches to be successful. In addi-
tion, there is an out-of-pocket cost to families interested in 
receiving these interventions in clinical settings. Moreover, 
the availability of interventions similar to those employed 
in the MTA study may be limited or nonexistent in some 
areas. Psychosocial treatments that are available likely vary 
in intensity and their adherence to evidence-based interven-
tion programs.
In the MTA study, the parents of only 1 of 289   children 
randomly assigned to receive psychosocial treatment (in psy-
chosocial treatment alone and combined treatment groups) 
refused to initiate psychosocial treatment.2 Of those who 
participated in the intervention, attendance at treatment 
sessions was high. Families attended an average of 77.8% 
of parent training sessions and 91% of possible summer 
treatment program days.2 However, the MTA study did not 
measure whether parents actually implemented psychosocial 
treatments as intended. Although parents who failed to 
attend sessions could not learn the parenting skills taught, 
being present at sessions did not ensure that parents either 
learned or   implemented the parenting skills taught.10 Efforts 
to   disseminate parent training sessions in community settings 
highlight potential challenges related to session attendance. 
Barkley et al11 offered manualized and well-validated   parent Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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  training groups (10 sessions followed by 4 booster   sessions) 
to parents of disruptive preschool age children. Thirty-three   
percent of parents did not attend any session, 25% of parents 
attended 1–4 sessions, 29% attended 5–8 sessions, and 13% 
attended 9–14 sessions.11 The authors speculate that poor 
attendance contributed to the intervention’s lack of benefit. 
Despite its potential importance as a mediator of treatment 
outcome, attendance is under-reported in studies of psycho-
social treatment among parents of children with ADHD.10 
In addition, there are few estimates of utilization of psycho-
social treatments. Among children with ADHD in North 
Florida, USA, in 1995, 25% received multimodal treatment 
that included psychosocial treatments.12 We are not aware 
of any such estimates among a nationally   representative 
sample.
Medication
The most widely evaluated approach to treating ADHD has 
been the use of different types of medications, particularly 
stimulant medications. The MTA medication algorithm 
started with a 28-day, double-blind, daily-switch titration of 
methylphenidate hydrochloride at a range of dosages to deter-
mine the best starting dosage.13 Similar to previous research, 
77% of children in the MTA group had a positive response to 
methylphenidate.14 Among those children who did not, about 
half had a positive response to a trial of dextroamphetamine.14 
Subsequently, children had monthly visits with a pharmaco-
therapist to monitor benefit and side effects and adjust dosage 
and/or medication to optimize response. Adjustment decisions 
were based on information obtained from children, parents, 
and teachers on a monthly basis. By the end of 14 months 
of medication treatment, only 29% of children remained on 
the original medication dosage.15 The average number of 
  adjustments was two per child.15
Fifty-six percent of children who received the MTA 
medication algorithm (without any psychosocial treatment) 
improved to the point of ADHD symptom remission by the 
end of the 14-month study.9 Side effects from medication 
were common, with 50% of children reporting mild, 
11% moderate, and 3% severe side effects at some time 
during the 14 months of treatment.2 In clinical settings, 
families often incur an out-of-pocket cost to obtain 
medication. In addition, medication management obtained 
in primary care settings likely differs from MTA procedures 
with regard to initial titration (eg, open-label upward titration 
rather than a blinded, placebo-controlled trial) and frequency 
of monitoring after the child is stable (eg, every 3–6 months 
rather than monthly).3 In addition, there are often   logistical 
barriers to obtaining feedback from teachers to inform 
  medication management decisions.16
In the MTA study, the parents of 18 of 289 children (6.2%) 
randomly assigned to receive medication (in medication alone 
and combined treatment groups) refused to initiate medica-
tion, and an additional 20 parents (6.9%) discontinued medica-
tion some time after their child’s initial titration was complete.2 
Despite coordinated research efforts to optimize adherence 
(eg, pill counts, intermittent saliva measurement to monitor 
methylphenidate taking, and encouragement of families to 
reschedule missed visits),2 medication use varied considerably 
among children in the MTA study. Just over half of children 
(136/254 = 53.5%) had detectable levels of methylphenidate 
every time a readable saliva measurement was obtained during 
the 14-month study.17 Medication adherence was a significant 
mediator of symptom reduction in the MTA study.13 Since 
the MTA study was published in 1999 there have been few 
estimates of ADHD medication use in community-based 
clinical samples. One such study, which included a sample 
representative of the US population in 2000–2002, reported 
that Caucasian children were more than twice as likely to 
have received treatment for ADHD (5.8%) than African-
American (2.8%) or Hispanic (2.4%) children.18 Another 
study employed a sample representative of the US population 
in 2003 and found that only 56.3% of children with reported 
ADHD diagnosis were being treated with medication at the 
time of the survey.19 Medication treatment rates for children 
diagnosed with ADHD varied widely by state, with a range 
from 40.6% in California to 68.5% in Nebraska.19 Analysis of 
California Medicaid claims (2000–2003) demonstrated that 
30% of children experience a 30-day gap in ADHD medication 
supply after receiving their initial prescription.20 The average 
time from initiation of ADHD medication to experiencing a 
30-day gap in treatment was ,150 days.20 Less than half of 
these children resumed ADHD treatment within 90 days after 
experiencing a gap in medication supply.20 Among Medicaid 
recipients in California20 and Texas,21 use of extended-release 
ADHD medications, compared with immediate-release medi-
cations, predicted greater persistence with medication. In a 
study of children with ADHD cared for in Kaiser Permanente 
of Northern California, a nonprofit integrated health care 
delivery system, medication copayment amount was found 
to be inversely related to duration of medication treatment 
(ie, lower out-of-pocket expense for filling a prescription 
related to longer persistence with medication treatment).22 
The current literature on changes in ADHD   medication 
use over time is limited by reliance on large pharmacy and/
or claims databases that lack linkage to the child’s clinical Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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treatment plan. Thus, it is impossible to know the proportion 
of children who discontinue medication use because they are 
able to achieve their goals for treatment without medication 
versus those who continue to struggle and discontinue medi-
cation for other reasons.
Combined treatment
Combined treatment involves receipt of both the psychosocial 
and medication treatments described above. At the end of the 
14-month MTA study, 68% of children who received com-
bined treatment improved to the point of symptom remission.9 
In addition, children who received combined treatment ended 
the 14-month study on a lower dose (18% less medication 
per day) than those in the medication only group.15 This is 
noteworthy because side effects, when present, can become 
more severe as dosages increase.14 The shortcomings of each 
modality involved in combined treatment are listed in this 
review within the description of each treatment option. The 
cumulative effect of shortcomings, such as out-of-pocket 
cost, may weigh significantly in the treatment planning pro-
cess for families with limited resources. Utilization of these 
modalities is described previously.
ADHD treatment planning: a series  
of preference-sensitive decisions
The MTA study demonstrated the comparative efficacy of 
psychosocial treatment alone, medication treatment alone, 
and combined treatment. As reviewed previously, the chance 
of symptom remission and potential shortcomings (eg, harms 
and costs) vary across these treatment conditions. As a result, 
ADHD treatment guidelines recognize all three options as 
medically reasonable.3,4 These guidelines stress the importance 
of taking into account family goals, preferences, cultural 
values, and concerns when developing a treatment plan.3,4 
The best initial treatment choice for the individual child 
depends on how an informed patient and parent(s) value the 
benefits relative to the potential harms/costs, as well as their 
ability to implement each option. Such decisions have been 
described as preference sensitive.23 As families accrue experi-
ence with one or more treatment modalities and recognize the 
actual benefits and harms/cost experienced by their child, the 
best treatment plan becomes one that strikes an acceptable 
balance between enabling progress toward current and future 
child/family goals while minimizing any harms/costs.
Patient and caregiver preferences
Our current understanding of patient and parent ADHD 
treatment preferences is based on quantitative research that 
assesses the construct of treatment acceptability and qualita-
tive and quantitative research that assesses preferences from a 
broader perspective. Each method contributes to the literature 
on what matters most to patients and parents when selecting 
ADHD treatments. In this review we highlight the key find-
ings, limitations, and unanswered questions.
Treatment acceptability
Studies of treatment acceptability among parents of children 
with ADHD are reviewed here. These studies have employed 
a variety of measures: 1) Treatment Evaluation   Inventory 
(TEI),24–26 2) Modified TEI,27 3) Adapted TEI Short Form,28 
4) Treatment Acceptability Questionnaire (TAQ),29 5) ADHD 
Knowledge and Opinion Scale (AKOS),30 6)   Modified 
AKOS,31 and 7) AKOS-Revised (AKOS-R).32 The common-
alities and differences between these scales with regard to the 
measurement of the “acceptability” construct are summarized 
in Table 1. All scales ask respondents to rate their agreement 
with a series of statements, and all generate a total score, 
with higher scores indicating greater acceptability. Unlike 
Table 1 Comparison of acceptability measures
Measure Item content
Treatment 
acceptable
Benefit 
expected
Treatment 
appropriate
Treatment 
liked
Willing 
to use
Devoid of 
bad side effects
TEI (Kazdin,24 Liu et al,25 and  
Gage and Wilson26)
X X X X X
Modified TEI ( Johnston and Fine27) X X X X X
Adapted TEI Short Form  
( Johnston et al28)
X X
Treatment Acceptability Questionnaire 
(Krain et al29)
X X X X X
AKOS (Rostain et al30) X X X X
Modified AKOS (Corkum et al31) X X X X
AKOS-R (Bennett et al32) X X X X
Abbreviations: TEI, Treatment Evaluation Inventory; AKOS, ADHD Knowledge and Opinion Scale; AKOS-R, ADHD Knowledge and Opinion Scale-Revised.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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versions of the TEI and TAQ, which have a single scale that 
can be completed in reference to various treatment options/
modalities, versions of the AKOS have separate scales that are 
specific for medication acceptability, psychosocial treatment 
acceptability, and psychosocial treatment feasibility.
Relative acceptability of ADHD  
treatment modalities
At the time of diagnosis, parents25,29 and children25 view 
psychosocial treatment as a more acceptable option than 
medication. One study found that ADHD knowledge at the 
time of diagnosis was positively correlated with acceptability 
of psychosocial treatment but not medication.31 Another study 
found that medication acceptability at the time of diagnosis 
was significantly higher among Caucasian parents compared 
with non-Caucasian parents (25% of sample).29 Actual 
experience with medication can increase parent-reported 
acceptability of medication treatment for ADHD.25,27 
Interestingly, increased acceptability of medication after 
the initial medication trial was related to increased parent 
knowledge of ADHD and ADHD treatment modalities25 
and not to the degree of child symptom reduction.25,27 With 
experience, some parents may come to find combination 
treatment most acceptable.25,26
Acceptability of psychosocial treatments 
among experienced parents
Among parents with past experience with psychosocial 
treatments, views of effectiveness were positively cor-
related with acceptability of psychosocial treatments in 
one study28 and were unrelated in another study.32 One 
study found that psychosocial treatment acceptability (but 
not psychosocial treatment feasibility) was higher among 
mothers than among fathers.32 The same study found that 
psychosocial treatment acceptability for both mothers and 
fathers was positively correlated with children’s external-
izing problems.32 Psychosocial treatment acceptability was 
also higher among mothers who knew an acquaintance 
with ADHD than among those who did not.32 One study 
found that parent acceptability of psychosocial treatments 
decreased after participating for 12 months in either par-
ent training or support groups.31 It is not clear whether this 
was due to perceived lack of effectiveness or other factors. 
Another study found that ADHD knowledge among fathers 
was positively correlated with past participation in psycho-
social treatments.30
No study found psychosocial treatment acceptability 
to be related to initiation (attending at least one session) of 
recommended psychosocial treatment29,31,32 or the number of 
sessions attended.32 It is noteworthy that there was limited 
variability in the high ratings of psychosocial treatment 
acceptability in two of the three studies that examined this 
relationship.29,31 One study found that ADHD knowledge 
predicted attending at least one parent training or support 
group.31
Acceptability of medication treatments 
among experienced parents
Among parents with past experience with medication treat-
ment, views of effectiveness were not related to medication 
acceptability in one study28 but were positively   correlated with 
medication acceptability among mothers (but not fathers) in 
another study.32 Among mothers, ADHD knowledge 
was negatively correlated with medication   acceptability 
in one study30 but positively correlated with medication 
acceptability for both mothers and fathers in another study.32 
One study found no significant difference between mothers 
and fathers on medication acceptability.32 Side effect ratings 
were negatively correlated with   medication acceptability 
among mothers but not fathers.32
Research on the relationship between acceptability 
and medication adherence has mixed findings. One study 
found that medication acceptability and ADHD knowledge 
predicted implementing the recommendation to initiate a 
trial of medication (eg, taking at least one   methylphenidate 
or placebo pill),31 but another study found no such 
  relationship.32 Krain et al29 found that significantly more 
Caucasian children than non-Caucasian children (79% vs 
27%) initiated medication (eg, ingestion of at least one pill) 
during the follow-up period (eg, average 3.7 months). After 
  controlling for race, acceptability ratings significantly 
predicted initiation of medication.29 Johnston and Fine27 
reported that following a medication titration, medication 
adherence (ie, composite score comprising missed pills; 
missed appointments; saliva methylphenidate; and parent-, 
teacher-, and physician-reported compliance) over 3 months 
of treatment was not related to acceptability scores (either 
before or after the initial trial of medication), consumer 
satisfaction, treatment response, or recommended dosage. 
Likewise, Corkum et al31 found no relationship between 
acceptability and adherence. In this study, the adherent 
category was defined by taking $50% of pills based on pill 
count. Based on this definition, 36/68 (53%) adhered to 
treatment, with those randomized to medication being more 
adherent than those randomized to placebo (25/35 = 74% vs 
11/34 = 32%). By 12 months, parent knowledge of ADHD Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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increased significantly, but ADHD knowledge was not 
related to adherence.
Limitations of acceptability research
Acceptability research among parents of children with 
ADHD has several limitations. First, studies employ 
different measures of acceptability and include samples 
that vary considerably with regard to their past experience 
with ADHD treatment modalities. These factors make it 
challenging to interpret contradictory findings across studies. 
Second, only two of the eight studies reviewed assessed 
the relative acceptability of combined treatment (eg, both 
psychosocial and medication treatment).25,26 This appears to 
be an important distinction, as combined treatment may be 
viewed more favorably than either treatment in isolation.26 
Third, the child’s perspective on acceptability is almost 
completely neglected. Only one study collected these 
responses from children at diagnosis,25 and no attempt was 
made to ascertain whether the child’s view of acceptability 
changed after trying treatment. Likewise, few studies exam-
ined how the views of fathers30,32 and minorities29 might 
differ. Fourth, there are few longitudinal studies that assess 
change in acceptability over time,25,27,31 and these studies are 
limited by attrition (eg, only 27/50 completed follow-up, with 
those initiating medication more likely to complete surveys)25 
and selection bias (eg, sample included only those willing to 
try medication27 or willing to be randomized to a 12-month 
treatment trial).31 Finally, analyses related to prediction of 
medication adherence may be confounded by the inclusion 
of children receiving a placebo.31 Adherence was extremely 
poor in the placebo group and may reflect discontinuation 
due to lack of effectiveness.31
Summary of acceptability studies
It seems clear that psychosocial treatments are generally 
more acceptable to parents than medication initially and that 
acceptability can change over time as parents garner valuable 
experience of managing ADHD with a variety of treatment 
modalities. However, acceptability alone has not been 
shown to predict implementation of   psychosocial treatment, 
which is likely influenced by a variety of   factors, such as 
service availability and feasibility of   family attendance 
(eg, time and affordability). Likewise, the relationship 
between acceptability and medication initiation appears 
  inconsistent. Continuing medication after a titration trial 
is likely related to a variety of factors (ie, perceived need, 
perceived   benefit, perceived side effects/concerns, patient 
acceptance, social support, and cost), of which acceptability 
is just one. Therefore, the construct of “acceptability” appears 
to have limited explanatory value in understanding child and 
caregiver ADHD treatment preferences. As such, we look to 
other bodies of literature for additional insights.
Qualitative and quantitative research 
assessing treatment preferences
Qualitative research methods are another way to better 
understand child and parent preferences about ADHD 
treatment. By allowing themes to emerge, rather than 
limiting inquiry to predefined constructs expected to explain 
a   phenomenon, qualitative studies have enabled parents and 
children with ADHD to identify aspects of treatment that 
are important to them, using their own words. In addition, 
quantitative research that has built on these qualitative 
research studies has contributed important insights by 
exploring a variety of constructs identified by parents and 
children. This literature, which is reviewed below, spans the 
long and winding road traveled by families from the onset 
of child problem behaviors to entering the medical system, 
receiving a diagnosis, negotiating the initial treatment plan, 
and subsequently revisiting and revising the treatment plan. 
Collectively, this literature illustrates that treatment prefer-
ences are often dynamic, informed by real-world experience 
with a variety of ADHD treatments, and context dependent 
as family goals/priorities evolve and progress toward these 
target outcomes is appraised.
Parent treatment preferences
The initial decision to seek medical help for ADHD symptoms 
is influenced by a parent’s explanatory model of ADHD 
(eg, parental beliefs about etiology, expected time course, 
  severity, parental worries, preferred treatments, and desired 
treatment outcomes). One study examined such beliefs among 
parents of children “at risk” for ADHD who subsequently met 
diagnostic criteria for ADHD based on parent reports on the 
Diagnostic Interview Schedule for Children Version IV.33 In 
this study, parents of untreated children, compared with parents 
of children who had received psychosocial and/or   medication 
treatment for ADHD in the past year, were less likely to 
1) believe that ADHD would have a long time course, 2) voice 
  concern about their child having a behavioral or emotional dis-
turbance, and 3) state a goal related to improved child   emotional 
functioning (eg, self-esteem and happiness).33 Among parents 
of untreated children,   two-thirds did not perceive a need for 
treatment, and 45% had   negative   expectations for treatment.33 
Another   qualitative study   identified four   treatment trajectories 
among families: 1) delay to   diagnosis, 2) initial   nonmedication Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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  treatment pattern, 3) reluctant receipt of diagnosis, and 4) 
rapid engagement in medication treatment.34 Treatment 
trajectories are   influenced by parent explanatory models, 
extended networks (eg,   family members, friends, religious 
leaders, school officials, and clinicians), and medical utiliza-
tion factors.34–36 Of note, families whose explanatory model 
closely parallel the biomedical model for ADHD (either from 
the time of diagnosis or after reframing) appear more likely 
to engage and maintain use of medication.34,35,37 Parents in 
the initial nonmedication treatment pattern choose to start 
with “less or no harm approaches”.34 Home care approaches 
utilized by parents range from those consistent with evidence-
based psychosocial treatment principles to those based more 
on popular myths (eg, elimination of sugar from diet).5–7,38–40 
Many parents of children with ADHD or at risk for ADHD 
believe that ADHD medications are overprescribed by 
doctors.41–43 Some parents prefer behavior modification and 
are reluctant to initiate medication.33,35,39,42,44 Despite this 
reluctance, many parents feel like they have exhausted par-
enting approaches and must resort to trying medication.35,36   
Parents who seek treatment are often driven by their   worries 
about the consequences of their child’s problems if left 
untreated.35,36,39,45 Inclusion of medication in the treatment 
plan is also facilitated by parent acceptance of the diagno-
sis of ADHD34,35 and recognition of their child’s functional 
impairments.34,35 Trying medication and/or contrasting time 
on and off medication helps parents to understand the effects 
and/or side effects for their child and informs subsequent 
decisions about continuing medication.35,36,46,47 A common 
barrier to trying a full range of dosages is family resistance to 
increasing the dosage after seeing improvement in their child’s 
behavior on the initial (eg, lowest) dose.48 Parents tend to prefer 
medications that have a long duration.49 Some parents come to 
view medication as necessary to controlling ADHD symptoms 
enough so that they can then achieve some limited success with 
psychosocial techniques.50 Parents continue to experience fears 
and worries related to the potential for long-term side effects, 
even if their child shows marked improvement.35,36,39,45,51 This 
phenomenon is especially pertinent given ongoing public 
discussion of the effect of stimulant medications on growth52,53 
and the   possible linkage between sudden cardiac death and the 
use of ADHD medications.54–58
Cultural variations in parent  
treatment preferences
Parental beliefs about ADHD help explain cultural variations 
seen in disparities in the rate of medication initiation.19,59,60 
Understanding ADHD as a medical illness61–63 and accepting 
medication treatment is more common among well-educated, 
affluent, and Caucasian families33,41,64 and among mothers65 
rather than fathers.66,67 Parents from less affluent or minority 
ethnic backgrounds may have underlying beliefs that 
contribute to lower rates of medication utilization for ADHD. 
Whether these beliefs constitute well-informed preferences 
is debatable. Qualitative studies have shed some light on 
these subcultural beliefs. Studies among Latino parents dem-
onstrate a lack of trust and shared understanding about the 
child’s problem34 and a preference for treatment options other 
than medication because they understand medication to be 
addictive, dulling of cognitive processes, and inappropriate 
for behavioral problems.68,69 African-American parents report 
1) distrust of ADHD as a diagnosis and of physicians who 
are quick to prescribe medication, 2) concern that stimulants 
will lead to drug abuse later in life, and 3) lack of support 
for medical treatment from their social networks.37,43,70–74 
Lack of support from social networks is not surprising given 
the largely negative beliefs and attitudes held about the use 
of psychoactive medications in children75 and the lower 
likelihood among minorities of espousing the belief that 
ADHD is a real disorder.76
Child and adolescent  
treatment preferences
Child and adolescent treatment preferences are an understud-
ied area. Studies have documented that 22%–50% of   children 
dislike taking medication for ADHD.67,77,78 In   addition, 
40%–65% of children avoid taking their medication.42,78 
Common avoidance tactics include   arguments with 
  parents and/or refusal to take it, throwing it away if no 
one is   watching, pretending to take   medication and then 
  throwing it away, or deliberately failing to remind a par-
ent who forgot to give it.78 Common reasons for avoidance 
include dislike of pills, embarrassment/social stigma, side 
effects,   negative effect on self-esteem, interference with 
activities (eg, sports   performance), and concern about 
addiction.42,44,78,79   Children in these studies also reported a 
lack of perceived need for medication, which may relate 
to the consistent finding that children with ADHD have 
  unrealistically high   self-belief about their skills and 
competence.80–85 In   addition, many children do not perceive 
any benefit from taking medication.44,67,78,86 Child and parent 
appraisal of medication effectiveness   disagrees in 25%–33% 
of cases.87 Twelve   percent of children report that they would 
discontinue   treatment if given the choice.67,77 Given the per-
vasive nature of child dislike and avoidance of   medication, 
it is not   surprising that   oppositional symptoms have been Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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associated with poor treatment adherence,88 and parents 
have endorsed child reluctance to take their   medication as 
a major reason for discontinuing treatment.36,42,89 Beyond 
avoiding medication, some children simply forget to take 
their medication.90,91
Treatment preferences change over time
In early work conducted by Firestone, the major reasons 
parents gave for stopping medication were that they were 
not comfortable with the idea of medicating their children or 
that their children were reluctant to take their medication.89 
Following the initial titration, side effects, when present, 
were not cited by parents as an important factor in their 
decision to discontinue treatment.89 In 2005, 16 parents of 
children with ADHD who had stopped taking medication 
were asked open-ended questions about the reasons for 
discontinuation.92 The most common reasons offered were 
side effect experiences (n = 6), summer medication break 
(n = 3), and trying to keep the child off medication to see 
whether ADHD would remit (n = 2). Three qualitative 
studies further depict parent decision making for their child 
with ADHD.35,36,45 Parents described medication decisions 
as a complex balancing act, with concerns about past and 
present experiences of adverse effects weighed against the 
functional improvements seen at home and at school. In 
addition, parents also considered an uncertain and unpredict-
able future, with concerns about possible long-term risks of 
medication weighed against their goals and expectations for 
their child’s future. In addition, this dilemma does not end 
after a decision has been made and acted on. Rather, parents 
continually justified and re-evaluated decisions long after 
they had been made.
Limitations of qualitative and quantitative 
research assessing treatment preferences
Qualitative studies are limited by small, geographically con-
fined samples. Results from these qualitative studies cannot 
be generalized to all children with ADHD or their parents. 
However, qualitative research provides important insights 
into poorly understood phenomena that can subsequently 
be studied using quantitative methods to better   characterize 
the prevalence of the phenomena and/or test implied 
  hypotheses.93 The research conducted by Bussing et al92 
represents the only prospective longitudinal study, leaving 
the majority of studies based on cross-sectional data. Both 
qualitative and quantitative studies reviewed are limited 
by a greater focus on medication rather than   psychosocial 
  treatments. There are plausible explanations for this. 
First, medication has long been a more   controversial and 
  polarizing topic among parents and the media than psycho-
social treatment. As such, it has been a popular topic for 
research. In addition,   medication is widely available, so the 
decision of whether or not to try medication is faced by 
nearly every parent of a child diagnosed with ADHD. In con-
trast, psychosocial treatments, although highly acceptable 
to parents, vary in availability, cost, and quality. As a result, 
utilization of psychosocial treatments may be less about 
parent preference and more about barriers to access in a 
resource-constrained environment. Moreover, there are more 
datasets (eg,   Medicaid) available to investigate utilization 
of medication than psychosocial treatments. Unfortunately, 
the current ADHD treatment preference literature does 
not adequately account for availability of services when 
  assessing   preferences. It is possible that parent preferences 
might change if evidence-based psychosocial treatments 
were   readily   available. It may be that parents might show 
more preference for psychosocial treatment with greater 
availability. It is also possible that parents might show less 
preference with greater availability due to trying psycho-
social treatments and finding that they did not fully address 
impairments.
Summary of qualitative and quantitative 
research assessing treatment preferences
After a child is diagnosed with ADHD, a variety of factors 
influence the initial selection of treatment modalities that 
are utilized. Initial parent and child preferences are shaped 
by their beliefs about the nature of the child’s problems and by 
information (and misinformation) received from a variety of 
sources, including social networks, the media, and health care 
providers. Subsequently, preferences become further informed 
by personal experience with various treatment modalities. Over 
time, treatment plans are revisited and revised (ie, treatment 
modalities are added and subtracted, and/or current approaches 
are modified) as families work with their health care team to 
establish a treatment plan that helps their child achieve goals 
while minimizing harms and costs. This process of optimiz-
ing care is similar to the family/self-management processes 
described for other chronic   conditions.94 Even when treatment 
plans are congruent with well-informed patient/parent pref-
erences and values, there can be barriers to implementation 
and/or persistence with treatment. Children can forget to take 
  medication, and parents might forget to give medication. 
  Families can struggle with the out-of-pocket costs for medi-
cation and/or   psychosocial   treatments. Access to high-quality 
psychosocial   treatments may be limited. When available, Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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there are   additional   barriers to learning and implementing 
  psychosocial treatment strategies.
Discussion
There are multiple treatments for ADHD that are effective. 
Because the treatment options differ on benefits and risks/
costs, the best choice is preference sensitive and depends on 
how an informed patient/parent values the tradeoffs between 
options.23 There are many publications examining variation 
in treatment utilization among children with ADHD. Most 
have focused on medication, as this is the most widely 
available treatment modality, and there are multiple sources 
of data available for analysis. However, these datasets are 
devoid of information about patient/  parent preferences and 
  knowledge regarding the likelihood of treatment outcomes 
(eg, benefits and risks/costs). Therefore, studies have not been 
able to distinguish between “unwarranted” and “  warranted” 
sources of variation. For example, the nearly two-fold 
variation in medication use between children diagnosed with 
ADHD in Nebraska and California19 would be   unwarranted 
if not   consistent with the distribution of informed patient/ 
parent treatment preferences.23 Studies are needed to better 
  characterize the amount of unwarranted variation in ADHD 
treatment patterns. Certainly, strategies are needed to ensure 
that 1) patients/parents are well informed about likely   benefits 
and risks/costs of treatment and 2) patient/parent goals, 
  preferences, and values are elicited and discussed. Shared 
decision making is one process to accomplish these objectives. 
Using shared decision-making tools, practitioners communi-
cate information on the options, outcomes, probabilities, and 
scientific uncertainties, and patients/parents communicate the 
personal value they place on the benefits versus harms so that 
agreement on the best strategy can be reached.95   Studies are 
needed to test shared decision-making interventions among 
parents of children with ADHD. In addition, studies are 
needed to determine the extent to which psychosocial treat-
ments are excluded from the treatment plan due to family 
preference rather than poor access to services or physicians 
underestimating parent preferences for this modality.
As a chronic condition, it is natural for patient/  parent 
goals, preferences, and values to evolve over time.   Treatment 
plans must be revised to reflect these changes and   progress 
made toward goals. It is not clear how often patient/parents 
and physicians explicitly set and/or revise goals for   treatment, 
although there is some evidence that goals are infrequently 
documented in the medical record.96,97 In   addition, it is not 
clear whether goals set are specific,   measurable,   attainable, 
relevant, and time bound. These dimensions are   important in 
increasing the chance that goal setting leads to   improvement.98 
Likewise, it is not clear how often patient/parent preferences 
and   values are elicited and discussed. In one study, only 44% 
of parents of a child with psychosocial problems reported 
that their child’s doctor always asked about his/her ideas and 
opinions when planning care for their child.99 Measuring 
meaningful outcomes over time is essential in order to help 
appraise progress toward goals.3 The American Academy 
of Pediatrics recommends a wide range of methods to 
obtain information about progress on target symptoms, 
  including office interviews, telephone conversations, teacher 
  narratives, periodic behavior report cards, and behavioral 
ratings.3 The behavioral ratings commonly collected in 
practice (eg, Connors and Vanderbilt Rating Scales) focus 
on symptoms and impairment.   Tracking symptoms may be 
a good proxy for other functional outcomes given the strong 
negative correlation observed between ADHD symptoms and 
health-related quality of life (ie, lower symptoms related to 
better quality of life).100–105 However, there is evidence that 
impairment often persists despite a reduction in ADHD 
symptoms.106   Therefore,   collection of impairment and poten-
tially other measures may add value as adaptive   functioning 
outcomes appear important to patients/parents.107,108 There 
is a   significant dropoff in the number of parent and teacher 
behavioral ratings that are obtained by physicians over time.106 
It is not clear to what extent this   phenomenon is based on 
1) a conscious decision to discontinue   monitoring based on 
child symptom remission documented on a previous check-
list or 2)   challenges for parents and physicians to sustain 
  engagement in ongoing monitoring activities in the absence 
of an ADHD-  precipitated child/family crisis. Regardless, 
the absence of such data makes it difficult to understand the 
changes in treatment utilization that occur over time. In the 
absence of symptom remission and/or goal attainment, what 
factors contribute to treatment discontinuation? Investigators 
from the MTA recently identified the need to address this 
gap in the literature as they stated: “It is clear that additional 
studies are needed to characterize who starts and who stops 
treatment with medication, and for what reasons, during the 
course of long-term treatment”.109
Conclusions
Treatment planning for children with ADHD is a dynamic 
  process. Ideally, this process includes consideration of 
  scientific evidence about the efficacy of treatments as well as 
patient/parent goals, preferences, and values. There are chal-
lenges to ensure that patient/parent preferences are   consistently 
well informed, elicited, and discussed in the treatment Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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planning process. Interventions are needed to promote such 
  interactions. Such research is a necessary step that will enable 
more   meaningful conclusions to be drawn about the appropri-
ateness of treatment utilization rates in a given population.
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